Department of Pharmacology (M.J.A., H.M.M., S.A.T.), Graduate Program in Neuroscience (M.J.A., S.A.T.), and Molecular Pharmacology and Therapeutics Graduate Program (H.M.M., S.A.T.), University of Minnesota Medical School, Minneapolis, Minnesota; State Key Laboratory of Membrane Biology, Peking University School of Life Sciences (A.D., Y.L.), IDG/McGovern Institute for Brain Research (A.D., Y.L.), and Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies (A.D., Y.L.), Peking University, Beijing, China; and Chinese Institute for Brain Research, Beijing, China (Y.L.).
Department of Pharmacology (M.J.A., H.M.M., S.A.T.), Graduate Program in Neuroscience (M.J.A., S.A.T.), and Molecular Pharmacology and Therapeutics Graduate Program (H.M.M., S.A.T.), University of Minnesota Medical School, Minneapolis, Minnesota; State Key Laboratory of Membrane Biology, Peking University School of Life Sciences (A.D., Y.L.), IDG/McGovern Institute for Brain Research (A.D., Y.L.), and Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies (A.D., Y.L.), Peking University, Beijing, China; and Chinese Institute for Brain Research, Beijing, China (Y.L.)
Mol Pharmacol. 2023 Feb;103(2):100-112. doi: 10.1124/molpharm.122.000555. Epub 2022 Nov 15.
The endocannabinoid system (ECS) modulates synaptic function to regulate many aspects of neurophysiology. It adapts to environmental changes and is affected by disease. Thus, the ECS presents an important target for therapeutic development. Despite recent interest in cannabinoid-based treatments, few preclinical studies are conducted in human systems. Human induced pluripotent stem cells (hiPSCs) provide one possible solution to this issue. However, it is not known if these cells have a fully functional ECS. Here, we show that hiPSC-derived neuron/astrocyte cultures exhibit a complete ECS. Using Ca imaging and a genetically encoded endocannabinoid sensor, we demonstrate that they not only respond to exogenously applied cannabinoids but also produce and metabolize endocannabinoids. Synaptically driven [Ca] spiking activity was inhibited (EC = 48 ± 13 nM) by the efficacious agonist [R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrolol [1,2,3-de]-1,4-benzoxazin-yl]-(1-naphthalenyl)methanone mesylate] (Win 55,212-2) and by the endogenous ligand 2-arachidonoyl glycerol (2-AG; EC = 2.0 ± 0.6 µm). The effects of Win 55212-2 were blocked by a CB receptor-selective antagonist. Δ-Tetrahydrocannabinol acted as a partial agonist, maximally inhibiting synaptic activity by 47 ± 14% (EC = 1.4 ± 1.9 µm). Carbachol stimulated 2-AG production in a manner that was independent of Ca and blocked by selective inhibition of diacylglycerol lipase. 2-AG returned to basal levels via a process mediated by monoacylglycerol lipase as indicated by slowed recovery in cultures treated with 4-[(1,3-benzodioxol-5-yl)hydroxymethyl]-1-piperidinecarboxylic acid 4-nitrophenyl ester (JZL 184). Win 55,212-2 markedly desensitized CB receptor function following a 1-day exposure, whereas desensitization was incomplete following 7-day treatment with JZL 184. This human cell culture model is well suited for functional analysis of the ECS and as a platform for drug development. SIGNIFICANCE STATEMENT: Despite known differences between the human response to cannabinoids and that of other species, an in vitro human model demonstrating a fully functional endocannabinoid system has not been described. Human induced pluripotent stem cells (hiPSCs) can be obtained from skin samples and then reprogrammed into neurons for use in basic research and drug screening. Here, we show that hiPSC-derived neuronal cultures exhibit a complete endocannabinoid system suitable for mechanistic studies and drug discovery.
内源性大麻素系统(ECS)调节突触功能,从而调节神经生理学的许多方面。它适应环境变化并受疾病影响。因此,ECS 是治疗开发的重要目标。尽管最近对基于大麻素的治疗方法感兴趣,但很少在人体系统中进行临床前研究。人类诱导多能干细胞(hiPSC)为解决这个问题提供了一种可能的解决方案。然而,目前尚不清楚这些细胞是否具有完整的 ECS。在这里,我们表明 hiPSC 衍生的神经元/星形胶质细胞培养物表现出完整的 ECS。使用钙成像和基因编码的内源性大麻素传感器,我们证明它们不仅对外源性应用的大麻素做出反应,而且还产生和代谢内源性大麻素。通过突触驱动的 [Ca] 尖峰活动被有效的激动剂 [R(+)-[2,3-二氢-5-甲基-3-[(吗啉基)甲基]吡咯并[1,2,3-de]-1,4-苯并恶嗪基]-(1-萘基)甲酮甲磺酸盐](Win 55,212-2)和内源性配体 2-花生四烯酰甘油(2-AG;EC = 2.0 ± 0.6 µm)抑制(EC = 48 ± 13 nM)。Win 55212-2 的作用被 CB 受体选择性拮抗剂阻断。Δ-四氢大麻酚作为部分激动剂,最大程度地抑制突触活性 47 ± 14%(EC = 1.4 ± 1.9 µm)。Carbachol 以 Ca 独立的方式刺激 2-AG 的产生,并被选择性抑制二酰基甘油脂肪酶阻断。2-AG 通过单酰基甘油脂肪酶介导的过程返回基础水平,这表明用 4-[(1,3-苯并二恶唑-5-基)羟甲基]-1-哌啶羧酸 4-硝基苯酯(JZL 184)处理的培养物中恢复较慢。Win 55,212-2 在 1 天暴露后明显使 CB 受体功能脱敏,而用 JZL 184 处理 7 天后脱敏不完全。这种人类细胞培养模型非常适合 ECS 的功能分析以及药物开发的平台。 意义声明:尽管人类对大麻素的反应与其他物种已知存在差异,但尚未描述具有完整内源性大麻素系统的体外人类模型。人类诱导多能干细胞(hiPSC)可以从皮肤样本中获得,然后重编程为神经元,用于基础研究和药物筛选。在这里,我们表明 hiPSC 衍生的神经元培养物表现出完整的内源性大麻素系统,适用于机制研究和药物发现。